Loading company…
NOVACELL develops peptide-based therapies for cancer and autoimmune diseases.
Founded in 2000, NOVACELL develops peptide immunotherapies intended to strengthen immune responses to cancer and autoimmune diseases. The company is based in Pohang, South Korea. In September 2026, it raised KRW 1 billion in pre-IPO funding from Korea Investment Partners to support therapy development. The supplied information also describes plans to expand in the United States and Europe.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in